Health
SARS-CoV-2 replicon for high-throughput antiviral screening – DocWire News
J Gen Virol. 2021 May;102(5). doi: 10.1099/jgv.0.001583.ABSTRACTThe severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus, which is highly
J Gen Virol. 2021 May;102(5). doi: 10.1099/jgv.0.001583.
ABSTRACT
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus, which is highly pathogenic and classified as a biosafety level 3 (BSL-3) agent, has greatly threatened global health and efficacious antivirals are urgently needed. The high requirement of facilities to manipulate the live virus has limited the development of antiviral study. Here, we constructed a reporter replicon of SARS-CoV-2, which can be handled in a BSL-2…
-
Business15 hours ago10 ASX shares to buy after the market selloff
-
General19 hours ago‘We are here for you’: PM to bring help to flood zones
-
Business14 hours ago$10,000 invested in ANZ shares 5 years ago is now worth…
-
General17 hours agoWe’ve all talked about potential economic consequences for Australia of Trump’s policies. Now they’re happening